Chimerix — Investor Presentation (August 2023)
43 slides from Chimerix's investor presentation, Aug 3, 2023
Slide 1: Chimerix Corporate Presentation
Chimerix Corporate Presentation August 3, 2023
Slide 2: Forward-Looking Statements
2 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking stateme
Slide 3: Investment highlights
3 Investment highlights • Terminal disease with no effective therapeutic options • High awareness for program within neuro-oncology community • U.S. patent exclusivity through at least 2037 • Global revenue potential of ~$750m in first indication alone • Phase 2 study designed to isolate single agen
Slide 4: Deep pipeline across all development stages
4 Program Preclinical Phase 1 Phase 2 Registrational FDA review Collaborators Deep pipeline across all development stages ONC201 (dordaviprone) H3 K27M-mutant glioma (orphan drug,1 fast track2 and rare pediatric disease designations3) IITs- signal finding, multiple oncology indications/combinations
Slide 5: ONC201 (dordaviprone) Phase 2 Efficacy Analysis
ONC201 (dordaviprone) Phase 2 Efficacy Analysis
Slide 6: H3 K27M-mutant diffuse glioma: high unmet need
6 • H3 K27M mutation is predominantly found among diffuse midline gliomas (DMGs) in young adults and children • Frontline radiotherapy remains standard of care with transient benefit; resection often not feasible • DMGs harboring the H3 K27M mutation are WHO Grade IV; historically invariably lethal
Slide 7: Phase 2 efficacy for ONC201 in recurrent H3 K27M DMG
7 • ONC201 monotherapy exhibited durable, clinically meaningful efficacy in recurrent H3 K27M-mutant DMG - Overall Response Rate (ORR) of 30% (95% CI: 18 - 45%) by RANO HGG and/or LGG dual reader BICR - RANO-HGG criteria assessed by dual reader BICR • ORR 20% (95% CI: 10 – 34%) • Median Duration of
Slide 8: FDA-aligned criteria for Phase 2 efficacy analysis
8 Objective • To evaluate monotherapy efficacy of ONC201 in recurrent H3 K27M-mutant diffuse midline glioma Eligibility • Age ≥2yo and received ONC201 under studies ONC006, ONC013, ONC014, ONC016, or ONC018 • Diffuse glioma with a known H3 K27M mutation and involvement of a midline structure of the
Slide 9: ONC201 waterfall plot – 30% RANO HGG / LGG response
9 • Strict selection criteria to ensure responses attributable to single agent treatment • Responses require both imaging and clinical criteria • Dual reader blinded independent central review (BICR) • Growing consensus that assessment of enhancing and non-enhancing disease (RANO- HGG and RANO-LGG c
Slide 10: RANO-HGG responses observed across age groups
10 RANO-HGG responses observed across age groups Responses by age group: <18 years: 1/4 (25%) 18-40 years: 5/32 (16%) >40 years: 4/14 (29%) RANO-HGG response of 8-year-old subject suggests activity in this population ONC201 Ph 2 Efficacy Analysis by BICR in Recurrent H3 K27M-mutant Diffuse Midline G
Slide 11: RANO HGG response correlation to performance status
11 RANO HGG response correlation to performance status (PS) supports early-line trial Predictably, patients with higher PS were more likely to respond to treatment 100: 1/2 (50%) 90: 4/14 (29%) 80: 4/20 (20%) 70: 1/7 (14%) 60: 0/7 (0%) Supports hypothesis that treating earlier in disease course may
Slide 12: Clinically meaningful and durable RANO-HGG responses
12 Clinically meaningful and durable RANO-HGG responses SPD=sum of products of perpendicular diameters (target enhancing lesions per BICR) Only patients with measurable target enhancing lesions by BICR at baseline and with post-baseline evaluations are included. Three patients did not have on-treatm
Slide 13: ONC201 safety
13 Treatment-related Adverse Events, Integrated Safety Data Set, (N=211 glioma patients) 2 Related TEAEs All grades Grade > 3 Any Treatment-related AE 55.5% 11.8% Fatigue 21.8% 2.8% Nausea 20.4% 0 Vomiting 14.2% 0.5% Headache 8.5% 0.5% Lymphocyte count decreased 6.6% 0.5% Decreased appetite 5.7% 0 W
Slide 14: RANO responses correspond with survival & clinical benefit
14 All patients RANO HGG Responders RANO HGG and/or LGG Responders N 50 10 15 PFS at 12 months (number of patients censored) 30%1 90% (0) 67% (2) OS at 24 months (number of patients censored)2 35%1 80% (2) 53% (5) Corticosteroids response3 (number of patients evaluable) 47% (15) 100% (4) 100% (5) Pe
Slide 15: Strong rationale for phase 3 success relative to recent GBM trials
15 Experimental Agent Ph2 Design Biomarker Response criteria Confounded by anti-angiogenic pseudo response ORR Duration of response 6 month PFS Approved? ONC201– Ph2 rDMG Single agent H3 K27M RANO BICR No 20-30% 11.2 35% To be determined Temozolomide Single agent - Levin No 5% ? 21% Yes (OS) Bevaciz
Slide 16: ONC201 Phase 3 ACTION Study Summary
ONC201 Phase 3 ACTION Study Summary
Slide 17: Pivotal Phase 3 ACTION trial design
17 Now enrolling, a randomized, double-blind, placebo-controlled, multicenter international study in 450 newly diagnosed diffuse glioma patients whose tumor harbors an H3 K27M-mutation. Pivotal Phase 3 ACTION trial design 1. Excludes DIPG and spinal tumors • H3 K27M-mutant diffuse glioma1 • Radiatio
Slide 18: Unique aspects of ONC201 data support translation to phase 3 success
18 Multiple unique aspects to ONC201 data support translation to phase 3 success Isolated, durable single agent activity Consistency across multiple endpoints Enhanced activity not required, but likely • Responses not confounded by combination treatments • Responses were gradual, durable, and multi-
Slide 19: Design provides multiple paths for success
19 Design provides multiple paths for success Interim data expected in early 2025 and final data in 2026 Second OS Interim • ~246 events • Success at HR=0.64 Final OS • ~327 events • Success at HR=0.73 PFS by RANO HGG(2) • ~286 events • Success at HR=0.68 1. Overall Survival (OS) 2. Progression-free
Slide 20: Potential to increase ONC201 efficacy with dose schedule
20 Potential to increase ONC201 efficacy with dose schedule • Once per week ONC201 dosing effective as monotherapy in Phase 2 studies • Twice per week dosing on two consecutive days expected to increase duration of therapeutic exposure - Increased exposure time can increase glioma sensitivity to ONC
Slide 21: ONC201 Market Opportunity Assessment
ONC201 Market Opportunity Assessment
Slide 22: H3 K27M-mutant glioma patient population estimates
22 (1) Ostrom QT, et al. Neuro Oncol. 2022;24(Suppl 5):v1-v95; (2) Patient numbers and percentages are estimates (weighted avg per sample size) derived from a review of the literature from (2012-2023): (Aihara K, et al. Neuro Oncol. 2014;16(1):140-6; Feng J, et al. Hum Pathol. 2015;46(11):1626-32; S
Slide 23: H3 K27M-mutant glioma: rapid ramp to peak revenue expected
23 • No approved therapies for H3 K27M mutant glioma, ONC201 is the leading program targeting this mutation globally • Potential market opportunity ~$750 million • Approximately 5,000 patients in top seven markets • Ultra-orphan indication drug pricing • H3 K27M mutations most often in children / yo
Slide 24: Regulatory designations
24 Regulatory designations 1. Subject to continuation of Rare Pediatric Disease Voucher Program and proceeds from voucher will be split 50/50 with legacy Oncoceutics shareholders US - Orphan Drug Designation (ODD) (treatment of glioblastoma and treatment of malignant glioma) EU - ODD for treatment o
Slide 25: ONC201 interim efficacy results in dopamine-secreting tumors outside the brain
25 • Single agent responses in Ph 2 neuroendocrine trial of ONC201 observed in subset (paraganglioma) • Paraganglioma are adrenal-related tumors with elevated DRD2 expression • Five patients have been treated > 1 year • Fewer short-term and potential long-term toxicities than other paraganglioma the
Slide 26: ONC201 Mechanism of Action
ONC201 Mechanism of Action
Slide 27: ONC201 directly engages DRD2 and ClpP
27 • ONC201 can selectively induce apoptosis in cancer cells by altering the activity of two protein targets • DRD2 antagonism - DRD2 is a G protein-coupled neuroreceptor that regulates Ras signaling - ONC201 antagonizes DRD2, inhibiting Ras signaling pathways • ClpP agonism - ClpP normally degrades
Slide 28: H3 K27M glioma primed for ONC201 sensitivity
28 H3 K27M glioma primed for ONC201 sensitivity Chi et al., Society of Neuro-Oncology, 2017; Piccardo et al., Eur J. Nucl Med Mol Imaging, 2019 Ex vivo high grade glioma growth sensitivity to ONC201 by H3 status DRD2 pathway inhibited by ONC201 is enriched in H3 K27M glioma H3 K27M glioma often loca
Slide 29: H3 K27M central characteristic reversed by ONC201
29 H3 K27M central characteristic reversed by ONC201 https://www.cell.com/trends/cancer/fulltext/S2405-8033%2819%2930202-X; Zhang et al, Science Translational Medicine, 2023; Koshmann et al, AACR 2023 H3 K27M causes loss of global H3 K27 trimethylation (H3 K27me3-loss) Removal of H3 K27M mutation re
Slide 30: ONC206
ONC206
Slide 31: ONC206: oral brain penetrant DRD2 antagonist + ClpP agonist
31 ONC206: oral brain penetrant DRD2 antagonist + ClpP agonist 1. PDB 6CM4 2. PDB 6DL7 DRD21 ClpP2 ONC206• Second generation imipridone designed to expand to new indications • Efficacy in cell culture, xenograft and transgenic central nervous system (CNS) and other tumor models • Oral dose escalatio
Slide 32: ONC206 monotherapy active in models of CNS and other cancers
32 CNS Tumors Glioblastoma1 Medulloblastoma2 ONC206 monotherapy active in models of CNS and other cancers 1. Theeler et al, SNO 2020 2. Malhotra et al, ISPNO, 2020 3. Hu et al, Cancers 2020 4. Tucker et al, American Journal of Cancer Research, 2022 Weeks P<0.05 ARK1 Human Endometrial Cancer Xenograf
Slide 33: ONC206 dose escalation: pediatric and adult CNS tumors
33 ONC206 dose escalation: pediatric and adult CNS tumors • Monotherapy dose escalation trials enrolling in parallel for adult and pediatric CNS tumors • Response reported by investigator from early cohort (100mg QW) without H3 K27M mutation - 18-year-old patient with recurrent temporal lobe gliobla
Slide 34: Dose intensification expected to enhance duration of therapeutic exposure
34 • Consecutive day dosing may increase therapeutic response - In vitro data demonstrates enhanced efficacy with 72 hour sustained exposure - Toxicology data enables safe escalation to more prolonged exposures • Phase 1 trial data suggest a therapeutic and safe exposure possible with twice daily, t
Slide 35: ONC206 dose escalation increasing to more frequent dosing
35 ONC206 dose escalation increasing to more frequent dosing 1. Dose level 6 was conducted in adults only 2. Pediatric dose scaled by body weight • No DLTs observed with weekly dosing • Similar safety profile in adults and pediatrics • Majority of treatment-related AEs are mild to moderate • Most co
Slide 36: ~30,000 new cases of GBM annually in top 7 markets; >$2Bn opportunity
36 • GBM is a rapidly progressive disease with low survival rates, few drug approvals last 25 years: - Temozolomide (TMZ) approved 1999 - Bevacizumab approved 2009 • Existing therapies rarely offer durable effect - 3-year survival from diagnosis • Chimerix retains global operational rights to ONC206
Slide 37: Preclinical Development ONC212 and CMX521
Preclinical Development ONC212 and CMX521
Slide 38: ONC212: GPR132 + ClpP Agonist
38 • Distinct molecular target (GPR132) and efficacy profile relative to ONC201/ONC206 • Efficacy in preclinical models of advanced cancers • GLP-tox studies complete, potential to advance to IND • Partnerships established for early-stage clinical trials with Brown University and MD Anderson Cancer
Slide 39: CMX-521: anti-SARS-CoV-2 preclinical activity
39 • Ribonucleoside analog that is a viral polymerase inhibitor - Inhaled nebulized liquid aerosol formulation; minimal systemic exposure • Monotherapy efficacy in mouse-adapted SARS-CoV-2-MA10 model across multiple endpoints - Lung viral titer - Viral RNA parallel viral lung titer (plaque forming u
Slide 40: Corporate Update
Corporate Update
Slide 41: TEMBEXA deal term summary
41 Emergent BioSolutions is an experienced biodefense company collaborating with government agencies to protect public health Terms summary: • $238 million received upfront at closing in Q3 2022 • Up to an additional $124 million in potential BARDA procurement milestones • 20% royalty on future U.S.
Slide 42: Financial strength supports development through key catalysts
42 Financial strength supports development through key catalysts Fully funded Ph 3 program with multiple potential paths to approval First-Line H3 K27M-mutant diffuse glioma – The ACTION Study Trial initiated November 2022 Interim OS data expected early 2025, full OS data expected 2026 ONC206 in
Slide 43: Chimerix
Chimerix Corporate Presentation